SCHEMBL2103250

SCHEMBL2103250

Cc1ccc2ccccc2c1Cc1c[nH]cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TSHR P16473 4/20 0.41
▸ CYP2A6 P11509 3/20 0.41
▸ CYP1A2 P05177 2/20 0.41
▸ HSD17B10 Q99714 2/20 0.38
▸ CYP2C9 P11712 2/20 0.38
▸ CYP2C19 P33261 2/20 0.38
▸ SIRT2 Q8IXJ6 1/20 0.36
▸ HCAR1 Q9BXC0 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.35
▸ HIF1A Q16665 2/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ CASP1 P29466 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CASP7 P55210 1/20 0.34
▸ ATM Q13315 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CYP2D6 P10635 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6216103 0.81 PDE10A (0.40) CYP2A6CYP1A2HSD17B10CYP2C9CYP2C19
SCHEMBL2103783 0.80 TAAR1 (0.46) CYP1A2HSD17B10CYP2C9CYP2C19KMT2A
Hydrochloric Acid SCHEMBL6215054 0.79 PDE10A (0.39) CYP2A6CYP1A2KDM4ETDP1
SCHEMBL16042478 0.78 TSHR (0.58) TSHRCYP2A6CYP1A2HSD17B10CYP2C9
SCHEMBL29489290 0.76 TSHR (0.56) TSHRCYP2A6CYP1A2HSD17B10CYP2C9
Potassium SCHEMBL29978462 0.76 TSHR (0.56) TSHRCYP2A6CYP1A2HSD17B10CYP2C9
SCHEMBL29489289 0.76 TSHR (0.56) TSHRCYP2A6CYP1A2HSD17B10CYP2C9
SCHEMBL4629510 0.76 TAAR1 (0.40) HSD17B10ALDH1A1HPGDRAB9AKDM4E
SCHEMBL11050063 0.74 NOS2 (0.34) —
SCHEMBL6214324 0.74 PLAU (0.43) TSHRCYP2A6CYP2C19KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101374832-B Use of 4-imidazole derivatives for CNS disorders HOFFMANN LA ROCHE 2013-03-06 — — CN disclosed
US-8158668-B2 Methods for treating CNS disorders with 4-imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-04-17 — — US disclosed
EP-1981880-B1 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS HOFFMANN LA ROCHE (CH) 2010-02-24 — — EP disclosed
CN-101374832-A Use of 4-imidazole derivatives for CNS disorders HOFFMANN LA ROCHE (CH) 2009-02-25 — — CN disclosed
EP-1981880-A2 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS F.HOFFMANN-LA ROCHE AG (CH) 2008-10-22 — — EP disclosed
US-20070197622-A1 Methods for treating CNS disorders with 4-imidazole derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2007-08-23 — — US disclosed
WO-2007085556-A2 USE OF 4-IMIDAZOLE DERIVATIVES FOR CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2007-08-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197622-A1 Methods for treating CNS disorders with 4-imidazole derivatives CRY1, GPR119, MTNR1A TSHR 162/4885CYP2A6 455/4885CYP1A2 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback